Eisai entered into an agreement with BioArctic Neuroscience to acquire the exclusive global rights to develop, manufacture and market experimental Alzheimer's disease compound, BAN2401, currently in pre-clinical development. Financial terms of the deal were not disclosed.
As part of the agreement, BioArctic said it retains the right to market the monoclonal antibody in Nordic countries. Takeshi Shimizu, a spokesman for Eisai, commented that the company is planning the clinical trial schedule for BAN2401.
The compound was developed as part of a 2005 strategic alliance between Eisai and BioArctic to identify a potential immunotherapy for Alzheimer's disease.
To read more Top Story articles, click here.